Latest News and Press Releases
Want to stay updated on the latest news?
-
Phase 2 M-ACCEL trial in MASH met primary endpoint, with statistically significant reductions in liver fat observed in all HU6 treatment groups
-
First data from Rivus’ preclinical CMA pipeline showing potential as monotherapy and in combination with GLP-1s